高氧液联合化疗治疗恶性肿瘤患者的临床观察(1)
 |
| 第1页 |
参见附件(2108KB，2页)。
[摘要] 目的：对44例恶性肿瘤患者给予高氧液联合化疗，并与只接受化疗的对照组患者进行对比分析。方法：44例恶性肿瘤患者设为治疗组，给予一线标准方案化疗，同时给予高氧液静脉输入伴随化疗每日1次。对照组患者单独采用一线标准方案化疗。2周期后观察疗效、毒副反应、KPS改善情况以及中位生存期。结果：治疗组和对照组有效率分别为23.1%和18.2%，两组比较，差异无统计学意义(P>0.05)；两组中位生存期(MST)分别为31.3个月和29.8个月，两组比较，差异无统计学意义(P>0.05)；治疗组和对照组的KPS改善率分别为59.6%和36.8%，两组比较，差异有统计学意义(P<0.05)。两组副性反应基本相同。结论：恶性肿瘤患者进行化疗联合静脉输注高氧液，值得临床应用。
[关键词] 恶性肿瘤；高氧液；化疗
[中图分类号] R730.5[文献标识码]B[文章编号]1673-7210(2011)04(a)-178-02
Clinical analysis of hyperoxic solution combined with chemotherapy in the treatment of m alignant tumor patients
YANG Yaokun, ZHANG Yuechen, WANG Jianming
Department of Medical Oncology, the Second People′s Hospital of Fuxin City, Fuxin 123000, China
[Abstract] Objective: To assess the efficacy and toxicity of the combination of hyperoxic solution and chemotherapy on m alignant tumour. Methods: 44 m alignant tumor patients were enrolled into the study. They accepted the treatment of the first standard chemotherapy and hyperoxic solution. The treatment of chemotherapy and hyperoxic solution was repeated every 21-28 days. After two cycles of chemotherapy, the efficacy and toxicity were evaluated. The other 44 patients of the comparative group were only accepted the first standard chemotherapy. Results: The efficacious rates of the two groups were 23.1% (cured group) and 18.2% (comparative group), there was no significant difference (P>0.05). The median survival time(MST) of the two groups were 31.3 months and 29.8 months, there was no significant difference (P>0.05). The KPS improvement of the two groups were 59.6% and 36.8%, there was a significant difference (P<0.05). The toxicity of the two groups were almost close. Conclusion: It's benefit from hyperoxic solution combined with chemotherapy for the m alignant tumour patients. It's worthy of promotion.
[Key words] M alignant tumor; Hyperoxic solution; Chemotherapy
机体在许多病理生理过程中存在低氧，越来越多的实验证据表明在实体肿瘤发展过程中，普遍存在低氧的状况。低氧与肿瘤的恶性进展、血管新生、肿瘤细胞的侵入转移和治疗耐受密切相关[1]。恶性肿瘤的非手术治疗目前仍以放化疗为主，大多手术前后也要配合放化疗。在低氧情况下肿瘤放化疗多存在不敏感的问题[2]。因此，许多国外学者提出将乏氧细胞存在的多少作为判断肿瘤预后的重要指标[3]。通过减少肿瘤乏氧细胞提高抗肿瘤疗效是目前研究的方向之一。笔者对44例恶性肿瘤患者进行化疗联合静脉输注高氧液治疗，现将结果报道如下：
1 资料与方法
1.1 一般资料 ......
您现在查看是摘要介绍页，详见PDF附件(2108KB，2页)。